Invasive Fungal Infection Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: 09 February, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 7.21 billion |
|
Revenue forecast in 2030 |
US$ 10.36 billion |
|
Growth Rate |
CAGR of 4.10% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments covered |
Drug Type, Disease Type, and Region |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global invasive fungal infection therapeutics market was valued at US$ 7.21 billion in 2021 and is expected to witness a CAGR of 4.10% during the forecast period from 2022 to 2030.
Market Fundamentals
Invasive fungal infections (IFIs) are infections where fungi establish themselves in the deep tissues and cause protracted sickness. IFIs are typically found in immunosuppressed and disabled people, caused by yeasts and molds. The main cause of invasive fungal infection is weak immunity. The disease occurs in bloodstream infections (mycosis) or via secondary transmission to areas such as the eyes, liver, spleen, bone, heart valves, and the central nervous system.
[7564644]
Market Dynamics
The rising prevalence of fungal infections and the rising need for innovative treatments are propelling the market growth. This, in turn, is increasing research and development activities. The drugs are highly adopted for the treatment of azoles, polyenes, and echinocandins, and are influencing the market growth. Moreover, many pipeline drugs are anticipated to boost the market potential in the coming years. However, there are several market challenges, such as adverse effects or limited effectiveness of certain antifungal drugs. Moreover, there is a lack of awareness about invasive fungal infections and their treatments among healthcare providers and the general population, leading to under diagnosis and treatment. The limited number of drugs available for the treatment of invasive fungal infections, particularly those caused by more resistant species, is a major challenge for this market. The emergence of drug-resistant fungal strains, such as azole-resistant Aspergillus fumigatus, has increased the difficulty of treating invasive fungal infections and has limited the effectiveness of existing antifungal drugs.
The high cost of antifungal drugs and the associated healthcare costs, including hospitalization and laboratory tests, presents a major challenge for many patients and healthcare systems, particularly in low- and middle-income countries. The complex regulatory process for the approval of new antifungal drugs, including the requirement for extensive clinical trials and safety testing, presents a significant challenge for developing and commercializing new antifungal drugs.
Market Ecosystem
The global invasive fungal infection therapeutics market has been analyzed from three perspectives: Drug Type, Disease Type, and Region.
Invasive Fungal Infection Therapeutics Market by Drug Type
[86745654]
According to drug type, the global invasive fungal infection therapeutics market is segmented into polyenes, echinocandins, triazoles, flucytosine and others. The triazoles segment is dominating the global market in 2021. Patients undergoing chemotherapy and HSCT (hematopoietic stem cell transplantation) are recommended to use triazole antifungal drugs. Furthermore, triazoles offer a wide range of activities and higher safety standards. In addition, triazoles provide easy and enhanced absorption and distribution properties. Polyenes are a class of antifungal drugs that have been used for the treatment of invasive fungal infections. They work by binding to ergosterol, an important component of fungal cell membranes, leading to a disturbance in membrane function and cell death.
In recent years, the trend in the treatment of invasive fungal infections has shifted towards the use of more targeted and less toxic antifungal agents, such as echinocandins and azoles. However, polyenes still play an important role in the treatment of certain types of fungal infections, especially those caused by more resistant species. Additionally, there has been increasing interest in the combination of different antifungal drugs, including polyenes, to improve treatment outcomes and prevent the development of resistance.
Invasive Fungal Infection Therapeutics Market by Disease Type
According to disease type, the global invasive fungal infection therapeutics market is classified into invasive aspergillosis, coccidioidomycosis and scedosporiosis, candidaemia and invasive candidiasis cryptococcal meningitis, intra-abdominal candidiasis, mucormycosis, invasive rhinosinusitis, others (esophageal candidiasis, acute pulmonary histoplasmosis). Invasive candidiasis has the majority of the market share. Invasive candidiasis is caused by Candida (a type of fungus). Invasive candidiasis is a dangerous infection affecting the blood, heart, brain, eyes, bones, and other body regions. People with weak immunity are more prone to acquire the disease. Furthermore, increased organ transplant cases often lead to infection, as immunosuppressors are extensively used here. The market for antifungal drugs to treat invasive aspergillosis, a life-threatening fungal infection caused by Aspergillus species, has been growing in recent years. This growth is driven by several factors, including the increasing prevalence of immunocompromised patients, such as those with cancer or undergoing organ transplantation, and the increasing incidence of nosocomial (hospital-acquired) fungal infections. Additionally, the development of new antifungal drugs and the growing recognition of the importance of early diagnosis and prompt treatment of invasive aspergillosis are also contributing to the growth of this market.
Invasive Fungal Infection Therapeutics Market by Region
Geographically, the global invasive fungal infection therapeutics market has been segmented into North America, Europe, Asia Pacific, and the rest of the world. North America is dominating the market. Increased incidence of invasive fungal infection and growing public awareness of invasive fungal illnesses are two factors that are projected to drive the market in North America. The European region is characterized by rising public awareness and increased focus of pharmaceutical and biotechnological companies in introducing new and innovative products. Asia Pacific region market for invasive fungal infection therapeutics market is influenced by factors such as the increasing prevalence of diseases, rising awareness, and high investments in R&D. Japan has dominated the market in the Asia Pacific region.
In the Middle East and Africa region, the invasive fungal infection therapeutics is growing, driven by several factors, including the increasing prevalence of immunocompromised patients, such as those with HIV/AIDS, and the increasing incidence of nosocomial (hospital-acquired) fungal infections. Additionally, the increasing recognition of the importance of early diagnosis and prompt treatment of invasive fungal infections, as well as the improving healthcare infrastructure and increasing healthcare expenditure in many countries in the region, are also contributing to the growth of the Middle East & Africa invasive fungal infection therapeutics market. However, the market for antifungal therapeutics in the Middle East and Africa region is still in its nascent stage. It faces several challenges, including limited healthcare access and affordability, as well as a lack of awareness about invasive fungal infections and their treatments among healthcare providers and the general population. Despite these challenges, the invasive fungal infection therapeutics market in the Middle East and Africa region is expected to grow in the coming years, driven by increasing demand for new and more effective treatments and ongoing efforts to improve healthcare access and affordability.
Competitive Landscape
Some of the prominent players operating in the global invasive fungal infection therapeutics market are:
The rising prevalence of fungal infections and the rising need for innovative treatments propel market growth. This, in turn, is increasing research and development activities. Azoles, polyenes, and echinocandins are highly prescribed for treating invasive fungal infections, influencing the market growth. Moreover, many pipeline drugs are anticipated to boost the market potential in the coming years.
Some of the prominent players operating in the Invasive Fungal Infection Therapeutics market are Abbott Laboratories Inc., Cidara Therapeutics Inc., Basilea Pharmaceutical, Pfizer Inc., Astellas Pharma Inc., GSK plc, Merck & Co., Bayer AG, F2G Ltd., Scynexis, Inc., and Pulmocide Ltd., among others.
The global invasive fungal infections market can show limited growth due to adverse effects associated with antifungals.
Invasive fungal infections (IFIs) are conditions where fungi establish themselves in the deep tissues and organs and have caused a protracted sickness.
The global invasive fungal infection therapeutics market is expected to witness a CAGR of 4.10% during the forecast period from 2022 to 2030.
*Insights on financial performance is subject to availability of information in public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst